广誉远: 广誉远中药股份有限公司2025年半年度报告摘要

Core Viewpoint - Guangyuyuan Traditional Chinese Medicine Co., Ltd. reported significant growth in its financial performance for the first half of 2025, with increases in revenue, profit, and net assets compared to the previous year [1][2]. Financial Performance - Total assets reached approximately 2.45 billion RMB, an increase of 7.83% from the end of the previous year [1]. - Net assets attributable to shareholders increased by 4.90% to approximately 1.65 billion RMB [1]. - Operating revenue for the period was approximately 779.28 million RMB, reflecting an 18.14% increase compared to 659.60 million RMB in the same period last year [1]. - Total profit rose by 18.90% to approximately 86.63 million RMB, up from 72.86 million RMB [1]. - Net profit attributable to shareholders increased by 28.95% to approximately 76.86 million RMB, compared to 59.60 million RMB in the previous year [1]. - The net cash flow from operating activities was approximately 246.06 million RMB, a significant increase of 51.65% from 162.26 million RMB [1]. - The weighted average return on equity improved to 4.78%, up by 0.87 percentage points from 3.91% [1]. Shareholder Information - The largest shareholder, Shennong Technology Group Co., Ltd., holds 15.17% of the shares, amounting to approximately 74.23 million shares [2]. - Other notable shareholders include Jiang Shibo with 1.67% (approximately 8.19 million shares) and Hong Kong Central Clearing Limited with 1.15% (approximately 5.62 million shares) [2]. - The total number of shareholders as of the report date was 63,497 [1].